Taxanes in the treatment of head and neck cancer

Schrijvers, Dirk; Vermorken, Jan B.

doi:10.1097/01.cco.0000158735.91723.0e

Cited by 47 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A standard chemoradiotherapeutic regimen remains to be established. Recently, the combination of docetaxel (TXT) with CDDP has been applied in the management of head and neck SCC (HNSCC) [5]. We have developed a concurrent chemoradiotherapeutic regimen for HNSCC where weekly administration of low-dose CDDP and TXT is combined with conventionally fractionated radiotherapy [6], and phase II study is currently ongoing.…”

Section: Introductionmentioning

confidence: 99%

Impact of FDG-PET on Prediction of Clinical Outcome after Concurrent Chemoradiotherapy in Hypopharyngeal Carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of FDG-PET on Prediction of Clinical Outcome after Concurrent Chemoradiotherapy in Hypopharyngeal Carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Widely used in treating breast cancer, non-small-cell lung cancer, ovarian cancer, and head and neck cancer, docetaxel is one of the most effective chemotherapeutic agents in clinical use (Crown and O'leary, 2000;Schrijvers and Vermorken, 2005). Cytotoxicity stems from its ability to promote tubulin polymerization and formation of stable microtubules.…”

Section: Introductionmentioning

confidence: 99%

Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells

et al. 2007

View full text Add to dashboard Cite

Docetaxel is one of the most effective chemotherapeutic agents against cancer; nevertheless, some patients develop resistance. Unfortunately, their causes and mechanisms remain unknown. We created docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mitochondrial DNA (mtDNA) and reactive oxygen species (ROS) on docetaxel resistance. DRHEp2 had greatly increased mtDNA content. Reduction of mtDNA content in DRHEp2 by ethidium bromide treatment reduced the resistance. These results indicate the possible roles of mtDNA-coded enzymes in mitochondrial respiratory chain (MRC) in resistant mechanisms. Oligomycin A, an Fo-ATPase inhibitor, eliminated docetaxel resistance in DRHEp2; in contrast, inhibitors of other MRC did not. RNA interference targeted to Fo-ATPase d-subunit restored docetaxelinduced cytotoxicity to DRHEp2. These results indicate the roles of Fo-ATPase for resistant mechanisms. Docetaxel induced ROS generation in HEp2 but not in DRHEp2 and antioxidant pyrrolidine dithiocarbamate eliminated docetaxel-induced cytotoxicity, suggesting roles of ROS in docetaxel-induced cell death. Furthermore, inhibition of Fo-ATPase by Oligomycin A induced docetaxel-mediated ROS generation in DRHEp2. Taken together, DRHEp2 acquired docetaxel resistance through increasing Fo-ATPase, which led to diminish docetaxelinduced ROS generation and subsequently inhibited cell death. In conclusion, mtDNA plays an important role in developing docetaxel resistance through the reduction of ROS generation by regulating Fo-ATPase.

show abstract

“…Although both agents share a common mechanism of action involving tubulin polymer stabilization and cell-cycle arrest, docetaxel demonstrates a higher affinity for β-tubulin, a longer intracellular half-life, as well as the ability to promote stabilization of microtubules at significantly lower molar concentrations than paclitaxel (Schrijvers and Vermorken 2005). Although, in principle, both paclitaxel and docetaxel may be combined with PF to improve ICT efficacy (Kies et al 2006), the potential for overlapping neuropathy with paclitaxel and cisplatin – especially when both agents are used at the higher end of their dosage range – has been recognized as potentially significant.…”

Section: Chemotherapy Regimens Used For the Treatment Of Locally Advamentioning

confidence: 99%

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Rapidis

Sarlis²,

Lefèbvre

et al. 2008

TCRM

View full text Add to dashboard Cite

Squamous cell carcinoma of the head and neck (SCCHN) presents at a locally advanced (LA) stage in many patients. Chemotherapy has been successfully integrated into first-line treatment programs, either during or prior to radiotherapy (RT) – the cornerstone modality for local disease control of inoperable disease or when organ preservation is desired. Concomitant chemoradiotherapy (CCRT) provides an absolute survival benefit when compared with other types of locoregional therapy that exclude chemotherapy. Nonetheless, distant metastases still represent the most common cause of treatment failure. Consequently, adding induction chemotherapy (ICT) to definitive non-surgical local therapies with a curative intent has been vigorously explored in LA SCCHN. Recently, it has been shown that ICT using the combination of the taxane docetaxel with cisplatin–5-fluorouracil provides significant survival benefit over cisplatin–5-FU, when used before either definitive RT (TAX323 trial) or carboplatin-based CCRT (TAX324 trial). Docetaxel is also being investigated in metastatic or recurrent (M/R) disease, with promising initial results. It is very likely that the future management strategies of SCCHN will incorporate biologic agents as an add-on to docetaxel-containing schemas, administered either as ICT prior to CCRT in the LA setting or for the management of M/R disease.

show abstract

Taxanes in the treatment of head and neck cancer

Cited by 47 publications

References 29 publications

Impact of FDG-PET on Prediction of Clinical Outcome after Concurrent Chemoradiotherapy in Hypopharyngeal Carcinoma

Impact of FDG-PET on Prediction of Clinical Outcome after Concurrent Chemoradiotherapy in Hypopharyngeal Carcinoma

Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About